Tranexamic acid for patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of 2991 patients.

Hazem S GhaithMohamed Diaa GabraMahmoud Ahmed EbadaOlaoluwa Ezekiel DadaHieder Al-ShamiEshak I BahbahSarya SwedAbdul Karim GhaithUlrick Sidney KanmounyeIgnatius N EseneAhmed Negida

Published in: The International journal of neuroscience (2022)

In patients with aSAH, TXA significantly reduces the incidence of rebleeding and mortality from rebleeding. However, current evidence does not support any benefits in overall mortality, neurological outcome, delayed cerebral ischemia, or hydrocephalus.

Keyphrases

cerebral ischemia
subarachnoid hemorrhage
end stage renal disease
risk factors
cardiovascular events
chronic kidney disease
newly diagnosed
prognostic factors
patient reported